Halozyme projects $8.65-$9.00 non-GAAP EPS for 2026
Halozyme Therapeutics has raised its revenue outlook to $1.835B-$1.91B for 2026.
The company’s Q2 2026 management view highlighted ENHANZE royalty revenue growth and new deal momentum.
The revenue growth is attributed to meaningful upfront milestones, with Hypercon already showing progress as a second source of revenue.